Pretransplant Fasting Glucose Predicts New-Onset Diabetes after Liver Transplantation
Table 3
Posttransplant variables by development of NODAT.
NODAT−
NODAT+
Total
value
One year
FPG (mg/dL)
98 ± 11.5
148 ± 50
106 ± 30
—
Hgb A1C
5.4 ± 0.3
6.3 ± 1.3
5.6 ± 0.7
—
BMI
27.1 ± 5.4
29.0 ± 6.9
27.5 ± 5.8
0.07
Tacrolimus level (ng/mL)
10.8 ± 3.2
11.3 ± 3.3
10.9 ± 3.2
0.4
Primary IS, (%)
Tacrolimus
170 (91.4)
33 (84.6)
203 (90.2)
0.74
Cyclosporine
6 (3.2)
2 (5.1)
8 (3.6)
Sirolimus
10 (5.4)
3 (7.7)
13 (5.8)
Other
0
1 (2.6)
1 (0.4)
Steroid-treated rejection
0.2 ±.48
0.2 ±.47
0.2 ±.48
0.75
Cumulative steroid dose, mg
2811 ± 1447
2732 ± 1407
2797 ± 1437
0.75
NODAT
39 (17.3)
IFG, (%)
36 (16)
Total abnormal glucose homeostasis, (%)
75 (33.3)
Continuous variables presented as means with standard deviation. BMI: body mass index, FPG: fasting plasma glucose, Hgb A1C: Hemoglobin A1C, IFG: impaired fasting glucose, IS: immunosuppression, NODAT: new-onset diabetes after transplantation.